Sublinox receives Canadian approval

MEDA AB (OMX: MEDA A) said that Health canada has approved Sublinox for treatment of insomnia. Sublinox is a patented sublingual orally dissolving tablet of the well known substance zolpidem. Product launch is expected in Q4. The product will be commercialized via the joint venture of Meda and Valeant Pharmaceuticals International and represents the second product to come out of the joint venture.